Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 80

1.

Metabolic syndrome in mice induced by expressing a transcriptional activator in adipose tissue.

Zhang L, Zhou Y, Zhu AY, Li XQ, Mundt SS, Gao L, Lisnock J, Hernandez M, Alonso-Galicia M, Springer MS, O'Neill EA, Daugherty BL, Puig O.

Transgenic Res. 2012 Jun;21(3):633-44. doi: 10.1007/s11248-011-9562-2. Epub 2011 Oct 26.

PMID:
22038448
2.

Generation of porcine fibroblasts overexpressing 11β-HSD1 with adipose tissue-specific aP2 promoter as a porcine model of metabolic syndrome.

Jung EM, An BS, Kim YK, Jeong YH, Hwang WS, Jeung EB.

Mol Med Rep. 2013 Sep;8(3):751-6. doi: 10.3892/mmr.2013.1592. Epub 2013 Jul 17.

PMID:
23864280
3.

Metabolic syndrome without obesity: Hepatic overexpression of 11beta-hydroxysteroid dehydrogenase type 1 in transgenic mice.

Paterson JM, Morton NM, Fievet C, Kenyon CJ, Holmes MC, Staels B, Seckl JR, Mullins JJ.

Proc Natl Acad Sci U S A. 2004 May 4;101(18):7088-93. Epub 2004 Apr 26.

4.

Glucocorticoids and 11beta-hydroxysteroid dehydrogenase type 1 in obesity and the metabolic syndrome.

Stimson RH, Walker BR.

Minerva Endocrinol. 2007 Sep;32(3):141-59. Review.

PMID:
17912154
5.

Carbenoxolone treatment attenuates symptoms of metabolic syndrome and atherogenesis in obese, hyperlipidemic mice.

Nuotio-Antar AM, Hachey DL, Hasty AH.

Am J Physiol Endocrinol Metab. 2007 Dec;293(6):E1517-28. Epub 2007 Sep 18. Erratum in: Am J Physiol Endocrinol Metab. 2008 May;294(5):E993.

6.
7.

Bezafibrate regulates the expression and enzyme activity of 11beta-hydroxysteroid dehydrogenase type 1 in murine adipose tissue and 3T3-L1 adipocytes.

Nakano S, Inada Y, Masuzaki H, Tanaka T, Yasue S, Ishii T, Arai N, Ebihara K, Hosoda K, Maruyama K, Yamazaki Y, Shibata N, Nakao K.

Am J Physiol Endocrinol Metab. 2007 Apr;292(4):E1213-22. Epub 2006 Dec 26.

8.

Has natural selection in human populations produced two types of metabolic syndrome (with and without fatty liver)?

Caldwell SH, Ikura Y, Iezzoni JC, Liu Z.

J Gastroenterol Hepatol. 2007 Jun;22 Suppl 1:S11-9. Review. Erratum in: J Gastroenterol Hepatol. 2008 Mar;23(3):501-2.

PMID:
17567458
9.

Overexpression of 11beta-hydroxysteroid dehydrogenase type 1 in hepatic and visceral adipose tissue is associated with metabolic disorders in morbidly obese patients.

Baudrand R, Carvajal CA, Riquelme A, Morales M, Solis N, Pizarro M, Escalona A, Boza C, Pérez G, Domínguez A, Arrese M, Fardella CE.

Obes Surg. 2010 Jan;20(1):77-83. doi: 10.1007/s11695-009-9937-0. Epub 2009 Aug 19.

PMID:
19690925
10.

Glucocorticoids and 11beta-hydroxysteroid dehydrogenase in adipose tissue.

Seckl JR, Morton NM, Chapman KE, Walker BR.

Recent Prog Horm Res. 2004;59:359-93. Review.

PMID:
14749510
11.

Peroxisome proliferator-activated receptor-α agonist, Wy 14,643, improves metabolic indices, steatosis and ballooning in diabetic mice with non-alcoholic steatohepatitis.

Larter CZ, Yeh MM, Van Rooyen DM, Brooling J, Ghatora K, Farrell GC.

J Gastroenterol Hepatol. 2012 Feb;27(2):341-50. doi: 10.1111/j.1440-1746.2011.06939.x.

PMID:
21929649
13.

Dehydroepiandrosterone inhibits the amplification of glucocorticoid action in adipose tissue.

Apostolova G, Schweizer RA, Balazs Z, Kostadinova RM, Odermatt A.

Am J Physiol Endocrinol Metab. 2005 May;288(5):E957-64. Epub 2004 Dec 21.

14.

Type 2 diabetes and metabolic syndrome are associated with increased expression of 11beta-hydroxysteroid dehydrogenase 1 in obese subjects.

Alberti L, Girola A, Gilardini L, Conti A, Cattaldo S, Micheletto G, Invitti C.

Int J Obes (Lond). 2007 Dec;31(12):1826-31. Epub 2007 Jun 26.

PMID:
17593901
15.

Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 in obesity.

Wake DJ, Walker BR.

Endocrine. 2006 Feb;29(1):101-8. Review.

PMID:
16622297
16.

Upregulation of adipose 11-beta-hydroxysteroid dehydrogenase type 1 expression in ovariectomized rats is due to obesity rather than lack of estrogen.

Paulsen SK, Nielsen MP, Richelsen B, Bruun JM, Flyvbjerg A, Pedersen SB.

Obesity (Silver Spring). 2008 Apr;16(4):731-5. doi: 10.1038/oby.2008.2. Epub 2008 Jan 31.

17.

Dietary capsaicin reduces obesity-induced insulin resistance and hepatic steatosis in obese mice fed a high-fat diet.

Kang JH, Goto T, Han IS, Kawada T, Kim YM, Yu R.

Obesity (Silver Spring). 2010 Apr;18(4):780-7. doi: 10.1038/oby.2009.301. Epub 2009 Oct 1.

18.

Overexpression of 11β-hydroxysteroid dehydrogenase type 1 in visceral adipose tissue and portal hypercortisolism in non-alcoholic fatty liver disease.

Candia R, Riquelme A, Baudrand R, Carvajal CA, Morales M, Solís N, Pizarro M, Escalona A, Carrasco G, Boza C, Pérez G, Padilla O, Cerda J, Fardella CE, Arrese M.

Liver Int. 2012 Mar;32(3):392-9. doi: 10.1111/j.1478-3231.2011.02685.x. Epub 2011 Dec 4.

PMID:
22136330
19.

Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 as a promising therapeutic target.

Wamil M, Seckl JR.

Drug Discov Today. 2007 Jul;12(13-14):504-20. Epub 2007 Jun 27. Review.

PMID:
17631244
20.

[Novel transgenic mouse model of the metabolic syndrome].

Masuzaki H, Tanaka T, Nakao K.

Nihon Rinsho. 2004 Jun;62(6):1059-65. Review. Japanese.

PMID:
15206142

Supplemental Content

Support Center